- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Vaccination
- Arexvy
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- Adults (18-64 years)
- Fragile population
- People at high risk of STIs
- Immunocompromised host
- PrEP users
- People living with HIV
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- Respiratory syncytial virus
- Bordetella pertussis
- Respiratory syncytial virus infection
- Pertussis
- Blood sample
- Nasopharyngeal swab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Non pharmacological intervention
- Lung ultrasound
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Blood sample
- Pregnant women
- Community
- Arbovirus
- Vector-borne disease
- Zika virus
- Venezuelan equine encephalitis virus
- Arboviral disease
- Vector-borne disease
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Pregabalin
- Adults (18-64 years)
- General population
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- General population
- Infants (<1 year)
- Community
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Corticosteroid
- Methylprednisolone
- General population
- Infants (<1 year)
- Hospital
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Immunoadsorption
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- AZD3152/Sipavibart
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Hydroxy gas
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Outpatient clinic
- Community
- Primary care
- Non-hospital health centre
- Emergency department
- SARS-CoV-2
- Post-COVID-19
- Acute COVID-19
- Adults (18-64 years)
- General population
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Vaccination
- BNT166a
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post-COVID-19
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab